Form 4 for ETON Eton Pharmaceuticals, Inc.
Accepted 2021-11-19 00:00:00 ET · period of report 2021-11-17 · accession 0001493152-21-029375 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2021-11-19 | 2021-11-17 | ETON | Opaleye Management Inc. | 10% | S - Sale | $4.67 | -25.0K | 2.38M | -1% | -$116.8K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock, par value $0.001 per share | 2021-11-17 | S | D | 25,000 | $4.67 | 2,375,000 | I By Opaleye, L.P. | — | — | (F2) The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sale price of $4.6685. The range of sale prices on the transaction date was $4.62 to $4.671 per share. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each price. (F1) Represents securities owned directly by Opaleye, L.P. (the "Fund"). As the investment manager of the Fund, Opaleye Management Inc. may be deemed to beneficially own the securities owned directly by the Fund. |